ENOV
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Enovis Corporation
- Nom
- Enovis Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $1.2B
- Employés
- 7,802
- PDG
- Damien McDonald
- Site web
- https://www.enovis.com
- Marché
- DCIEPACFELEGHMGRCHLIO
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 20633 titres (~399591 USD)
- Insiders
- Engert OliverMcDonald Damien
- Total bought
-
$399,591
Avg buy (VWAP, 90d window) $19.30 vs last close $17.77 (-7.9%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-04
- Liquidity
- Liquid $36,480,609/day · 20d vol
- Last synced
-
2026-10-02 21:10:21
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Engert Oliver | Buy · P | 2,660 | $18.80 | $50,008 | Form 4 |
| 2026-09-04 | McDonald Damien | Buy · P | 13,035 | $19.15 | $249,620 | Form 4 |
| 2026-09-03 | Engert Oliver | Buy · P | 5,140 | $19.46 | $100,024 | Form 4 |
| 2026-09-02 | Engert Oliver | Buy · P | 2,458 | $20.32 | $49,947 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ENOV presents a meaningful event-driven signal — insider cluster buying (~$400k) paired with a Zacks upgrade post-acquisition — but these catalysts are severely undermined by deeply distressed fundamentals: negative…
The first sentence of the analysis written for ENOV on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.02 · operating margin -0.8% — readings disagree
Suggested stop 15.87, nearest stored support minus 0.5 ATR(10.7% under the last close). Reward/risk to the next stored resistance is 3.53. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 59.8% | 56.0% | 58.0% | 55.6% | 54.5% | |
| Ebit Margin | -50.0% | -36.3% | -2.8% | 1.4% | -6.5% | |
| Ebitda Margin | -36.9% | -22.8% | 9.9% | 15.5% | 11.9% | |
| Operating Profit Margin | -0.8% | -36.8% | -3.8% | -4.6% | -4.4% | |
| Pretax Profit Margin | -51.6% | -39.0% | -3.9% | -0.1% | -8.5% | |
| Continuous Operations Profit Margin | -52.6% | -39.3% | -3.2% | -2.4% | -7.2% | |
| Net Profit Margin | -52.7% | -39.2% | -1.9% | -0.9% | 5.0% | |
| Bottom Line Profit Margin | -52.7% | -39.2% | -1.9% | -0.9% | -7.2% | |
| Current Ratio | 2.017 | 2.167 | 2.426 | 1.407 | 2.250 | |
| Quick Ratio | 1.040 | 1.133 | 1.157 | 0.652 | 1.902 | |
| Solvency Ratio | -0.380 | -0.251 | 0.169 | 0.251 | 0.087 | |
| Cash Ratio | 0.061 | 0.091 | 0.098 | 0.043 | 0.665 | |
| Price To Earnings Ratio | -1.277 | -2.939 | -91.836 | -191.143 | -39.169 | |
| Price To Earnings Growth Ratio | -0.032 | -0.001 | -0.779 | 2.219 | 0.141 | |
| Forward Price To Earnings Growth Ratio | -0.032 | -0.001 | -0.779 | 2.219 | 0.141 | |
| Price To Earnings Diluted Ratio | -1.277 | -2.939 | -91.836 | -191.143 | -39.169 | |
| Price To Earnings Diluted Growth Ratio | -0.032 | -0.001 | -0.779 | 2.219 | 0.139 | |
| Price To Book Ratio | 1.016 | 0.947 | 0.893 | 0.839 | 0.876 | |
| Price To Sales Ratio | 0.673 | 1.151 | 1.788 | 1.851 | 2.837 | |
| Price To Free Cash Flow Ratio | 75.962 | -36.092 | 239.154 | -17.938 | 16.066 | |
| Price To Operating Cash Flow Ratio | 6.963 | 21.371 | 22.615 | -51.800 | 11.363 | |
| Debt To Assets Ratio | 0.360 | 0.298 | 0.119 | 0.078 | 0.254 | |
| Debt To Equity Ratio | 0.926 | 0.548 | 0.157 | 0.097 | 0.469 | |
| Debt To Capital Ratio | 0.481 | 0.354 | 0.136 | 0.089 | 0.319 | |
| Long Term Debt To Capital Ratio | 0.459 | 0.338 | 0.120 | 0.011 | 0.310 | |
| Financial Leverage Ratio | 2.574 | 1.842 | 1.319 | 1.239 | 1.844 | |
| Working Capital Turnover Ratio | 3.667 | 3.683 | 4.512 | 2.071 | 1.559 | |
| Operating Cash Flow Ratio | 0.363 | 0.215 | 0.365 | -0.099 | 0.348 | |
| Operating Cash Flow Sales Ratio | 0.097 | 0.054 | 0.079 | -0.036 | 0.250 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.092 | -0.592 | 0.095 | 2.888 | 0.707 | |
| Debt Service Coverage Ratio | -9.015 | -6.295 | 4.430 | 0.766 | 3.230 | |
| Interest Coverage Ratio | -0.542 | -13.585 | -3.327 | -2.853 | -2.157 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.637 | 5.668 | 6.259 | -0.229 | 12.015 | |
| Operating Cash Flow Coverage Ratio | 0.158 | 0.081 | 0.252 | -0.167 | 0.164 | |
| Capital Expenditure Coverage Ratio | 1.101 | 0.628 | 1.104 | -0.530 | 3.416 | |
| Dividend Paid And Capex Coverage Ratio | 1.101 | 0.628 | 1.104 | -0.530 | 3.416 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.440 | -7.862 | 20.933 | 13.257 | 32.487 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 59.8% | ▲3.8% | ▲3.0% |
| Ebit Margin | -50.0% | ▼-13.7% | ▼-31.2% |
| Ebitda Margin | -36.9% | ▼-14.1% | ▼-32.5% |
| Operating Profit Margin | -0.8% | ▲36.0% | ▲9.2% |
| Pretax Profit Margin | -51.6% | ▼-12.5% | ▼-30.9% |
| Continuous Operations Profit Margin | -52.6% | ▼-13.3% | ▼-31.6% |
| Net Profit Margin | -52.7% | ▼-13.5% | ▼-34.8% |
| Bottom Line Profit Margin | -52.7% | ▼-13.5% | ▼-32.3% |
| Current Ratio | 2.017 | ▼-0.150 | ▼-0.036 |
| Quick Ratio | 1.040 | ▼-0.092 | ▼-0.137 |
| Solvency Ratio | -0.380 | ▼-0.129 | ▼-0.355 |
| Cash Ratio | 0.061 | ▼-0.030 | ▼-0.131 |
| Price To Earnings Ratio | -1.277 | ▲1.662 | ▲63.996 |
| Price To Earnings Growth Ratio | -0.032 | ▼-0.031 | ▼-0.342 |
| Forward Price To Earnings Growth Ratio | -0.032 | ▼-0.031 | ▼-0.342 |
| Price To Earnings Diluted Ratio | -1.277 | ▲1.662 | ▲63.996 |
| Price To Earnings Diluted Growth Ratio | -0.032 | ▼-0.031 | ▼-0.341 |
| Price To Book Ratio | 1.016 | ▲0.069 | ▲0.102 |
| Price To Sales Ratio | 0.673 | ▼-0.478 | ▼-0.987 |
| Price To Free Cash Flow Ratio | 75.962 | ▲112.054 | ▲20.532 |
| Price To Operating Cash Flow Ratio | 6.963 | ▼-14.409 | ▲4.860 |
| Debt To Assets Ratio | 0.360 | ▲0.062 | ▲0.138 |
| Debt To Equity Ratio | 0.926 | ▲0.378 | ▲0.487 |
| Debt To Capital Ratio | 0.481 | ▲0.127 | ▲0.205 |
| Long Term Debt To Capital Ratio | 0.459 | ▲0.120 | ▲0.211 |
| Financial Leverage Ratio | 2.574 | ▲0.733 | ▲0.810 |
| Working Capital Turnover Ratio | 3.667 | ▼-0.016 | ▲0.569 |
| Operating Cash Flow Ratio | 0.363 | ▲0.148 | ▲0.125 |
| Operating Cash Flow Sales Ratio | 0.097 | ▲0.043 | ▲0.008 |
| Free Cash Flow Operating Cash Flow Ratio | 0.092 | ▲0.684 | ▼-0.546 |
| Debt Service Coverage Ratio | -9.015 | ▼-2.720 | ▼-7.638 |
| Interest Coverage Ratio | -0.542 | ▲13.043 | ▲3.951 |
| Short Term Operating Cash Flow Coverage Ratio | 3.637 | ▼-2.030 | ▼-1.833 |
| Operating Cash Flow Coverage Ratio | 0.158 | ▲0.077 | ▲0.060 |
| Capital Expenditure Coverage Ratio | 1.101 | ▲0.473 | ▼-0.043 |
| Dividend Paid And Capex Coverage Ratio | 1.101 | ▲0.473 | ▼-0.043 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.440 | ▲4.422 | ▼-14.515 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.51B | $2.43B | $3.05B | $2.89B | $4.05B | |
| Enterprise value | $2.86B | $3.78B | $3.55B | $3.20B | $5.53B | |
| EV / Sales | 1.27x | 1.79x | 2.08x | 2.05x | 3.88x | |
| EV / Op. cash flow | 13.14x | 33.32x | 26.32x | -57.36x | 15.53x | |
| EV / Free cash flow | 143.40x | -56.27x | 278.34x | -19.86x | 21.96x | |
| EV / EBITDA | -3.44x | -7.86x | 20.93x | 13.26x | 32.49x | |
| Net debt / EBITDA | -1.62x | -2.82x | 2.95x | 1.28x | 8.72x | |
| Current ratio | 2.02x | 2.17x | 2.43x | 1.41x | 2.25x | |
| Income quality | -0.18x | -0.14x | -4.06x | 4.75x | 4.67x | |
| Graham number | — | — | — | — | $53 | |
| Graham net-net | -$30 | -$28 | -$11 | -$7 | -$55 | |
| Tax burden | 102.2% | 100.3% | 49.5% | 642.4% | -58.8% | |
| Interest burden | 103.1% | 107.5% | 141.7% | -9.4% | 131.4% | |
| Working capital | $608.6M | $617.4M | $526.9M | $229.8M | $1.28B | |
| Invested capital | $3.14B | $4.10B | $4.05B | $3.63B | $4.68B | |
| Return on assets | -30.9% | -17.5% | -0.7% | -0.3% | 0.8% | |
| Operating ROA | -0.4% | -16.8% | -1.5% | -1.1% | -0.8% | |
| Return on tangible assets | -63.0% | -48.3% | -2.5% | -1.1% | 1.3% | |
| Return on equity | -79.5% | -32.2% | -1.0% | -0.4% | 1.6% | |
| Return on invested capital | -0.6% | -18.3% | -1.3% | -1.8% | -0.7% | |
| Return on capital employed | -0.6% | -18.5% | -1.6% | -1.9% | -0.8% | |
| Earnings yield | -78.3% | -34.0% | -1.1% | -0.5% | 1.8% | |
| Free cash flow yield | 1.3% | -2.8% | 0.4% | -5.6% | 6.2% | |
| Capex / Op. cash flow | 90.8% | 159.2% | 90.5% | -188.8% | 29.3% | |
| Capex / Depreciation | 67.0% | 63.5% | 56.3% | 48.0% | 39.6% | |
| Capex / Sales | 8.8% | 8.6% | 7.2% | 6.7% | 7.3% | |
| SG&A / Sales | 47.6% | 44.6% | 48.6% | 49.4% | 46.7% | |
| R&D / Sales | 5.4% | 4.3% | 4.4% | 3.9% | 3.4% | |
| Stock comp / Sales | 1.5% | 1.4% | 2.0% | 2.5% | 2.5% | |
| Intangibles / Total assets | 51.0% | 63.8% | 70.7% | 72.4% | 36.3% | |
| Days sales outstanding | 72d | 70d | 62d | 62d | 65d | |
| Days payables outstanding | 76d | 71d | 67d | 71d | 87d | |
| Operating cycle | 308d | 286d | 301d | 287d | 266d | |
| Cash conversion cycle | 232d | 215d | 234d | 216d | 178d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-03 What Makes Enovis (ENOV) a New Buy Stock Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-09-03 Enovis (ENOV) Loses 33% in 4 Weeks, Here''s Why a Trend Reversal May be Around the Corner Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 2026-09-02 Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
- 2026-09-01 Enovis Corporation (ENOV) M&A Call Transcript Enovis Corporation (ENOV) M&A Call Transcript
- 2026-09-01 Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.
- 2026-09-01 eCential Robotics Announces Binding Offer from Enovis eCential Robotics platform to join Enovis'' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
- 2026-09-01 Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes.
- 2026-08-31 Enovis to Participate in the 2026 Wells Fargo Healthcare Conference Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.
- 2026-08-21 Enovis Corporation: Arvis Is Disrupting The Health Care Industry Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV''s fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis''s growth potential is not.
- 2026-08-20 Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man''s Land Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Q2 results beat expectations, with 4% organic revenue growth and improved margins, but guidance now anticipates a more Q4-weighted second half. ENOV is making progress on cash flow conversion and deleveraging, and should reach sub-2.0x net debt/EBITDA within three years.